SCHEMBL24457802

SCHEMBL24457802

CNc1ncc2cc(-c3cc(N)ccc3C(F)(F)F)c(C)nc2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 6/20 0.42
▸ BRAF P15056 5/20 0.42
▸ RAF1 P04049 4/20 0.42
▸ KRAS P01116 3/20 0.42
▸ MAPK14 Q16539 3/20 0.42
▸ EIF2AK4 Q9P2K8 2/20 0.42
▸ MAPK13 O15264 1/20 0.42
▸ ABL1 P00519 1/20 0.42
▸ FYN P06241 1/20 0.42
▸ ARAF P10398 1/20 0.42
▸ SRC P12931 1/20 0.42
▸ EPHA2 P29317 1/20 0.42
▸ CSK P41240 1/20 0.42
▸ MAPK8 P45983 1/20 0.42
▸ MAPK9 P45984 1/20 0.42
▸ IRAK1 P51617 1/20 0.42
▸ MAPK12 P53778 1/20 0.42
▸ MAPK10 P53779 1/20 0.42
▸ EPHB4 P54760 1/20 0.42
▸ MAP2K5 Q13163 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29427284 0.84 RAF1 (0.46) KDRBRAFRAF1KRASMAPK14
SCHEMBL22612930 0.84 RAF1 (0.46) KDRBRAFRAF1KRASMAPK14
SCHEMBL29427288 0.84 RAF1 (0.46) KDRBRAFRAF1KRASMAPK14
SCHEMBL24457876 0.82 SIK2 (0.40) KDRBRAFRAF1KRASMAPK14
SCHEMBL24457818 0.80 RAF1 (0.39) KDRBRAFRAF1KRASMAPK14
SCHEMBL24457875 0.77 BRAF (0.48) KDRBRAFRAF1KRASMAPK14
SCHEMBL24457809 0.77 BRAF (0.48) KDRBRAFRAF1KRASMAPK14
SCHEMBL24457872 0.76 BRAF (0.48) KDRBRAFRAF1KRASMAPK14
SCHEMBL24457808 0.76 MAP4K4 (0.56) KDRBRAFRAF1KRASMAPK14
SCHEMBL24457869 0.75 PIK3CA (0.50) KDRBRAFMAPK14EIF2AK4LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912668-B2 GCN2 and perk kinase inhibitors and methods of use thereof DECIPHERA PHARMACEUTICALS, LLC (US) 2024-02-27 — — US disclosed
US-11912668-B2 GCN2 and perk kinase inhibitors and methods of use thereof DECIPHERA PHARMACEUTICALS, LLC (US) 2024-02-27 — — US disclosed
WO-2022109001-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC (US) 2022-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912668-B2 GCN2 and perk kinase inhibitors and methods of use thereof EIF2AK4, GCN1, MAPKAPK2 KDR 3047/4885BRAF 334/4885RAF1 428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback